Full Text View
Tabular View
No Study Results Posted
Related Studies
EVA: Evista Alendronate Comparison
This study has been completed.
Study NCT00035971   Information provided by Eli Lilly and Company
First Received: May 7, 2002   Last Updated: July 18, 2006   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Osteoporosis
More general conditions related to this trial
Bone Diseases
Bone Diseases, Metabolic
Musculoskeletal Diseases
Interventions listed in this trial
raloxifene HCI and alendronate Na
Additional drug interventions recognized in this trial
Alendronate
Raloxifene
More general drug interventions related to this trial
Bone Density Conservation Agents
Estrogen Antagonists
Estrogen Receptor Modulators
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Selective Estrogen Receptor Modulators
Sponsors listed in this trial
Eli Lilly and Company


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services